Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0123Keywords:
linguistic validation, patient reported outcome, prurigo, Prurigo Control Test, translationAbstract
Chronic prurigo (CPG), including prurigo nodularis (PN), is a neuroimmune-inflammatory skin condition characterized by persistent itching and fibrotic lesions. PN commonly affects older adults (>55 years) and imposes substantial disease burden, necessitating effective disease control. Prurigo Control Test (PCT) is the first validated, patient reported, disease control assessment test for PN/ CPG. To ensure broad accessibility and utility, cultural and linguistic adaptation of PCT is essential. We present the first comprehensive translation initiative of PCT into 18 widely spoken languages, beyond its original German and English versions: Arabic/Chinese (Simplified)/ Chinese (Traditional)/Czech/Danish/Dutch/Finnish/ French/Hebrew/Icelandic/Italian/Japanese/Korean/ Norwegian/Portuguese/Spanish/Swedish/Turkish. We followed best translation practices recommen ded by ISPOR, EMA and FDA ‒ conceptual analysis, forward/backward translation, author review, cognitive interviews, proofreading and finalization. The availability of PCT in multiple languages facilitates its global applicability and empowers physicians/caregivers/patients to assess the PN/CPG control using PCT in their preferred language, thereby enhancing implementation of this test across diverse clinical and cultural settings. The goal of translating this academically developed test while ensuring broader demographic representation (ages 18–80, diverse educational and occupational backgrounds) is to facilitate meaningful conversations between physicians and patients and optimize treatment decisions while transcending language barriers. To our knowledge, PCT is the first disease control assessment test specifically designed for PN/CPG to undergo such extensive linguistic adap-tation, contributing to the advancement of global dermatological assessment.
Downloads
References
Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059–1065. DOI: https://doi.org/10.1111/jdv.14570
Müller S, Zeidler C, Ständer S. Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol 2024; 25: 15–33. DOI: https://doi.org/10.1007/s40257-023-00818-z
Ständer S, Pereira MP, Berger T, Zeidler C, Augustin M, Bobko S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 2020; 5: e42–e42. DOI: https://doi.org/10.1097/itx.0000000000000042
Kwatra SG, Pereira MP, Misery L, Mollanazar NK, Shah P, Wiggins S. Prurigo nodularis: disease burden, clinical features and approach to management. Br J Dermatol 2025; 193: 642–652. DOI: https://doi.org/10.1093/bjd/ljaf213
Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol 2020; 140: 480–483. DOI: https://doi.org/10.1016/j.jid.2019.07.697
Aggarwal P, Choi J, Sutaria N, Roh YS, Wongvibulsin S, Williams KA, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol 2021; 46: 1277–1284. DOI: https://doi.org/10.1111/ced.14722
Olbrich H, Kridin K, Hernández G, Zirpel H, Sadik CD, Terheyden P, et al. Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study. EBioMedicine 2024; 103: 105123. DOI: https://doi.org/10.1016/j.ebiom.2024.105123
Janmohamed SR, Gwillim EC, Yousaf M, Patel KR, Silverberg JI. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis. Arch Dermatol Res 2021; 313: 669–677. DOI: https://doi.org/10.1007/s00403-020-02148-0
Murota H, Arima K, Yoshida T, Fujita H. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan. J Dermatol 2024; 51: 223–233. DOI: https://doi.org/10.1111/1346-8138.17045
Zeidler C, Pereira MP, Dugas M, Augustin M, Storck M, Weyer‐Elberich V, et al. The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non‐lesional skin. Acad Dermatol Venereol 2021; 35: 738–743. DOI: https://doi.org/10.1111/jdv.16929
Leis M, Fleming P, Lynde CW. Prurigo nodularis: review and emerging treatments. Skin Therapy Lett 2021; 26: 5–8.
Labib A, Ju T, Vander Does A, Yosipovitch G. Immunotargets and therapy for prurigo nodularis. Immunotargets Ther 2022; 11: 11–21. DOI: https://doi.org/10.2147/ITT.S316602
Ständer S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, et al. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol 2022; 36: 573–581. DOI: https://doi.org/10.1111/jdv.17870
Ständer S, Fofana F, Dias-Barbosa C, Rodriguez D, Budhiarso I, Jabbar-Lopez ZK, et al. The sleep disturbance numerical rating scale: content validity, psychometric validation, and meaningful within-patient change in prurigo nodularis. Dermatol Ther 2023; 13: 1587–1602. DOI: https://doi.org/10.1007/s13555-023-00962-8
Zeidler C, Pereira MP, Augustin M, Spellman M, Ständer S. Investigator’s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm Venereol 2021; 101: adv00401. DOI: https://doi.org/10.2340/00015555-3701
Zeidler C, Stander S, Rhoten S, Wratten S, Zhang D, Msihid J, et al. Validation of a scoring algorithm for the clinician-reported outcome tool “prurigo activity and severity (PAS)” based on clinical studies of dupilumab in adults with prurigo Nodularis. J Eur Acad Dermatol Venereol 2024; 38: 1954–1964. DOI: https://doi.org/10.1111/jdv.19961
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29: 1180–1190. DOI: https://doi.org/10.1038/s41591-023-02320-9
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606–613. DOI: https://doi.org/10.1046/j.1525-1497.2001.016009606.x
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092–1097. DOI: https://doi.org/10.1001/archinte.166.10.1092
Pereira MP, Ständer S. Assessment of severity and burden of pruritus. Allergol Int 2017; 66: 3–7. DOI: https://doi.org/10.1016/j.alit.2016.08.009
Metz M, Zeidler C, Hawro T, Pereira M, Maurer M, Bonnekoh H, et al. Development and validation of a patient-reported outcome measure to assess disease control in chronic prurigo. JAMA Dermatol 2024; 160: 187–193. DOI: https://doi.org/10.1001/jamadermatol.2023.5519
Albabtain B, Paudyal V, Cheema E, Bawazeer G, Alqahtani A, Bahatheq A, et al. Translation, cultural adaptation and validation of Patient Satisfaction with Pharmacist Services Questionnaire (PSPSQ) 2.0 into the Arabic language among people with diabetes. PLoS One 2024; 19: e0298848. DOI: https://doi.org/10.1371/journal.pone.0298848
Staumont-Sallé D, Taieb C, Merhand S, Shourick J. The atopic dermatitis control tool: a high-performance tool for optimal support. Acta Derm Venereol 2021; 101: adv00618. DOI: https://doi.org/10.2340/actadv.v101.750
Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133: 1365–1372. DOI: https://doi.org/10.1016/j.jaci.2013.12.1076
Asthma control test. [cited 2026 January].
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005; 8: 94–104. DOI: https://doi.org/10.1111/j.1524-4733.2005.04054.x
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79. DOI: https://doi.org/10.1186/1477-7525-4-79
Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Doc. Ref. EMEA/CHMP/EWP/139391/2004. London: European Medicines Agency; 2005.
Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol 2015; 68: 435–441. DOI: https://doi.org/10.1016/j.jclinepi.2014.11.021
Talley C, McKown S. Patient-reported outcome measure translation: an overview. Medical Writing 2018; 27: 26–29.
Linguistic validation of clinical outcomes assessments: a best-practice approach. [cited 2026 January].
Yook HJ, Lee JH. Prurigo nodularis: pathogenesis and the horizon of potential therapeutics. Int J Mol Sci 2024; 25: 5164. DOI: https://doi.org/10.3390/ijms25105164
Whang KA, Mahadevan V, Bakhshi PR, Williams KA, Gabriel S, Chavda R, et al. Prevalence of prurigo nodularis in the United States. J Allergy Clin Immunol Pract 2020; 8: 3240–3241. DOI: https://doi.org/10.1016/j.jaip.2020.05.051
Boozalis E, Tang O, Patel S, Semenov YR, Pereira MP, Stander S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 2018; 79: 714–719. DOI: https://doi.org/10.1016/j.jaad.2018.04.047
Augustin M, Garbe C, Hagenström K, Petersen J, Pereira MP, Ständer S. Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: a population‐based claims data analysis. Acad Dermatol Venereol 2021; 35: 2270–2276. DOI: https://doi.org/10.1111/jdv.17485
Acquadro C, Patrick DL, Eremenco S, Martin ML, Kuliś D, Correia H, et al. Emerging good practices for Translatability Assessment (TA) of Patient-Reported Outcome (PRO) measures. J Patient Rep Outcomes 2017; 2: 8. DOI: https://doi.org/10.1186/s41687-018-0035-8
Nikjooy A PhD, Jafari H PhD, Saba MA, Ebrahimi N, Mirzaei R MD. Patient assessment of constipation quality of life questionnaire: translation, cultural adaptation, reliability, and validity of the Persian version. Iran J Med Sci 2018; 43: 261–268.
Talbert M, McKown S, Gawlicki MC, Brandt BA, Angun C, Schulz C. Localization of activities and equivalence of movement in clinical outcomes assessments. Value Health 2013; 16: A597. DOI: https://doi.org/10.1016/j.jval.2013.08.1679
Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, et al. Multinational trials—recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report. Value Health 2009; 12: 430–440. DOI: https://doi.org/10.1111/j.1524-4733.2008.00471.x
Moreno-Serra R, Anaya-Montes M, León-Giraldo S, Bernal O. Addressing recall bias in (post-)conflict data collection and analysis: lessons from a large-scale health survey in Colombia. Confl Health 2022; 16: 14. DOI: https://doi.org/10.1186/s13031-022-00446-0
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
